院际转运前静脉溶栓与取栓的疗效及安全性
该研究分析两个前瞻性队列中前循环大血管闭塞、需从初级卒中中心转运取栓的患者,比较转运前启动静脉溶栓与未溶栓者的结局。经倾向评分重叠加权后,溶栓组3个月良好功能结局、优秀功能结局及转运期间再通率更高,任何颅内出血和症状性颅内出血风险未增加,但仅50%患者接受了溶栓。
要点
- 转运前静脉溶栓与更高转运期间再通率和3个月良好功能结局相关。
- 溶栓未增加任何颅内出血或症状性颅内出血风险。
- 仅50%转运患者接受溶栓,未溶栓主因超4.5小时窗或使用抗凝药。
核心结论
- 转运前静脉溶栓与转运期间再通改善及3个月功能结局改善相关,且未增加安全风险。
- 但仅50%患者实际接受转运前静脉溶栓,需探索扩大溶栓标准。
研究设计与样本
- 研究分析两个前瞻性队列中前循环大血管闭塞、从初级卒中中心转运取栓的患者,无论最终是否尝试取栓。
- 共纳入521例患者,260例(50%)在转运前接受静脉溶栓;采用倾向评分重叠加权平衡组间协变量。
主要发现
- 经倾向评分重叠加权后,溶栓组良好功能结局(mRS 0-2)的OR=2.17,95%CI=1.43-3.30,p<0.01。
- 溶栓组优秀功能结局(mRS 0-1)的OR=1.99,95%CI=1.21-3.25,p<0.01。
- 溶栓组转运期间再通的OR=5.64,95%CI=2.92-10.89,p<0.01。
- 任何颅内出血的OR=1.14,95%CI=0.76-1.70;症状性颅内出血的OR=0.73,95%CI=0.36-1.51,组间相似。
- 未溶栓主因包括超出4.5小时时间窗(58%)或使用抗凝药(21%)。
关键数值与推荐
- 良好功能结局定义为3个月mRS 0-2,优秀功能结局定义为mRS 0-1。
- 安全性结局为24小时任何颅内出血和症状性颅内出血。
临床怎么用
- 对于从初级卒中中心转运取栓的前循环大血管闭塞患者,可考虑在转运前启动静脉溶栓以改善再通和功能结局。
- 不应因担心颅内出血风险而常规放弃转运前静脉溶栓。
- 需关注超4.5小时时间窗和使用抗凝药的患者群体,探索扩大溶栓标准的可行性。
局限性
- 研究为前瞻性队列分析,非随机对照试验,尽管采用倾向评分重叠加权仍可能存在残余混杂。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with acute ischemic stroke and large vessel occlusion (LVO) often require transfer from primary stroke centers (PSCs) to thrombectomy-capable centers. This study assessed the efficacy and safety of intravenous thrombolysis (IVT) initiated before inter-hospital transfer. METHODS: Data from 2 prospective cohorts of patients with anterior circulation LVO transferred for thrombectomy from a PSC, regardless of whether thrombectomy was eventually attempted at the endovascular-capable center, were analyzed. Efficacy outcomes included good 3-month functional outcome (modified Rankin scale [mRS] = 0-2), excellent functional outcome (mRS = 0-1), and arterial recanalization during transfer. Safety outcomes included any intracerebral hemorrhage (ICH) and symptomatic ICH (sICH) at 24 hours. Propensity score with overlap weighting balanced the covariates between patients treated with IVT versus those without. RESULTS: Of 521 patients, 260 (50%) received IVT before transfer. IVT was withheld mainly due to being outside the 4.5-hour window (58%) or anticoagulant use (21%). Median age was 72 years, 55% were men, and median baseline National Institutes of Health Stroke Scale (NIHSS) was 15. After propensity score with overlap weighting, patients receiving IVT more frequently had good functional outcome (odds ratio [OR] = 2.17, 95% confidence interval [CI] = 1.43-3.30, p < 0.01), excellent functional outcome (OR = 1.99, 95% CI = 1.21-3.25, p < 0.01), and inter-facility recanalization (OR = 5.64, 95% CI = 2.92-10.89, p < 0.01) compared with patients not treated with IVT. Any ICH (OR = 1.14, 95% CI = 0.76-1.70) and sICH (OR = 0.73, 95% CI = 0.36-1.51) rates were similar between groups. INTERPRETATION: IVT before transfer was associated with improved recanalization and functional outcomes without increasing safety risks but is used in only 50% of patients. Expanding IVT criteria, including treatment beyond 4.5 hours and in anticoagulated patients, should be explored. ANN NEUROL 2025;98:871-880.
引用
- Seners P, Mlynash M, Ter Schiphorst A, et al. Intravenous Thrombolysis Use before Inter-Facility Transfer for Thrombectomy: Association with Efficacy and Safety Outcomes. Ann Neurol. 2025. PMID: 40536361. doi:10.1002/ana.27303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。